// App-Quantinova.ai

4181 : The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes

Researchers

Presenter

  • Richard B. Lock

Principal Investigators

  • Kathryn Evans

  • Connor D. Jones

  • Stephen W. Erickson

  • Beverly A. Teicher

  • TJ Unger

  • Yosef Landesman

  • Malcolm A. Smith

Medical Centers

  • Children's Cancer Institute, Sydney, Australia

  • RTI International, Research Triangle Park, NC

  • National Cancer Institute, Bethesda, MD

  • Karyopharm Therapeutics, Newton, MA

Locations

  • Australia

  • United States

Companies

  • Karyopharm Therapeut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematology-oncology disease

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Exportin 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02649790

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved